In short. A 503A compounding pharmacy is a state-licensed pharmacy that compounds on a prescription for an identified individual patient. Its state board of pharmacy licenses it; FDA sets the federal conditions it must meet: a valid patient-specific prescription, limits on which bulk substances it may use, no routine copies of a commercially available drug, and a cap on crossing state lines.
What a 503A pharmacy is
“503A” refers to section 503A of the Federal Food, Drug, and Cosmetic Act. FDA describes it this way: it “applies to human drug compounding by a licensed pharmacist within a state-licensed pharmacy or federal facility, or by a licensed physician, that is not registered with FDA as an outsourcing facility.” In other words: the pharmacy around the corner that compounds prescriptions, licensed by its state, and not registered with FDA as a 503B outsourcing facility. The Drug Quality and Security Act, which set out today’s two-track structure, was enacted on November 27, 2013.
Who oversees it
Licensing and day-to-day oversight come from the state board of pharmacy, as they do for any pharmacy in that state. FDA’s role is the federal one: 503A sets conditions the compounder must meet to be exempt from certain federal requirements. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness or quality. NABP keeps a list of every state board of pharmacy.
The patient-specific prescription
Under 503A, FDA says compounding “must be based on the receipt of a valid prescription for an identified individual patient. It can occur after the receipt of the prescription, or in limited quantities before the receipt of such a prescription.” So a 503A pharmacy can prepare ahead, but only in limited quantities and only for patients a prescriber has already written for. For a clinic this is the shape of a normal patient order: the prescriber writes it, the pharmacy compounds it, and the drug is tied to one named patient.
Which bulk substances it may use
A 503A pharmacy may not reach for just any bulk substance. FDA gives three routes: the substance must comply with an applicable USP or NF monograph and the USP compounding chapter, or be a component of a drug FDA has approved, or appear on FDA’s list of bulk drug substances acceptable for 503A compounding. A February 2019 final rule placed six substances on that list. A bulk substance must also come with a valid certificate of analysis and be manufactured by an establishment registered with FDA under section 510.
No routine copies of an approved drug
503A also says a compounder must not compound “regularly or in inordinate amounts any drug products that are essentially copies of a commercially available drug product.” For a clinic, that is the line between compounding for a patient who needs something specific and compounding as a roundabout way to sell what is already on the market. The prescriber’s documented, patient-specific reason is what keeps a compounded order on the right side of it.
Crossing state lines: the MOU cap
Section 503A limits how much of a 503A pharmacy’s compounded product may cross state lines. FDA describes the limit as tied to the memorandum of understanding between states and FDA: the limit “depends on whether the compounder is located in a state that has entered into” an MOU with FDA, and FDA published the final MOU in October 2020. FDA describes the share as five per cent or more depending on the MOU. Either way, shipping across state lines is a capped, not unlimited, part of a 503A pharmacy’s practice.
How a 503A differs from a 503B
A 503B outsourcing facility registers with FDA, compounds under current good manufacturing practice, and is inspected by FDA on a risk-based schedule. It “is not required to be a licensed pharmacy,” and it “may or may not obtain prescriptions for identified individual patients”: it may fill patient-specific prescriptions, and it may also supply compounded drugs in response to an order from a health care provider — a hospital or a clinic — that is not for an identified individual patient, such as for office stock. FDA’s 503B track also carries no explicit federal condition on interstate distribution, where 503A does.
| 503A compounding pharmacy | 503B outsourcing facility | |
|---|---|---|
| Who licenses it | The state board of pharmacy (or a federal facility or licensed physician) | Registers with FDA; not required to be a licensed pharmacy |
| Prescription | A valid prescription for an identified individual patient | May fill patient-specific prescriptions or supply a facility without one |
| Office stock | Not covered by the federal exemption for 503A compounding | May supply a health care facility for office stock |
| Interstate distribution | Capped under section 503A, tied to the MOU | No explicit federal condition |
Where TrueRoute fits
TrueRoute is ordering software, not a pharmacy, and never prescribes. Orders are filled by licensed pharmacies in our network, and each pharmacy holds its own state licensure. A patient prescription and an office-use purchase are separate orders in TrueRoute; office-use purchasing is available once your account’s program is set up. Prescribers on the account are NPI-validated and clinic-attested. Every order keeps its status, payment and fulfillment on one append-only record.
503A vs 503B: what a clinic can order, and how · The pharmacy network